Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,600 shares, a decline of 23.3% from the September 15th total of 6,000 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 26,800 shares, the short-interest ratio is currently 0.2 days.
Barinthus Biotherapeutics Trading Down 1.7 %
Shares of BRNS stock traded down $0.02 during trading on Friday, hitting $1.17. The company’s stock had a trading volume of 5,993 shares, compared to its average volume of 39,316. The business has a fifty day moving average of $1.26 and a 200-day moving average of $1.77. The company has a market cap of $46.12 million, a PE ratio of -0.71 and a beta of -0.53. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.10.
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.01). As a group, research analysts predict that Barinthus Biotherapeutics will post -1.71 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on BRNS
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. M&G Plc purchased a new stake in shares of Barinthus Biotherapeutics during the second quarter worth about $7,276,000. Alphabet Inc. bought a new stake in Barinthus Biotherapeutics during the 2nd quarter valued at about $2,119,000. DC Funds LP purchased a new position in Barinthus Biotherapeutics in the 1st quarter worth approximately $1,528,000. BlueCrest Capital Management Ltd bought a new position in shares of Barinthus Biotherapeutics during the first quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Featured Articles
- Five stocks we like better than Barinthus Biotherapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.